|
1
|
Garcia M, Jemal A, Ward EM, et al: Global
Cancer Facts and Figures 2007. GA: American Cancer Society;
Atlanta: 2007
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Verdecchia A, Santaquilani M and Sant M:
Survival for cancer patients in Europe. Ann Ist Super Sanita.
45:315–324. 2009.PubMed/NCBI
|
|
4
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
5
|
Deng N, Goh LK, Wang H, et al: A
comprehensive survey of genomic alterations in gastric cancer
reveals systematic patterns of molecular exclusivity and
co-occurrence among distinct therapeutic targets. Gut. 61:673–684.
2012. View Article : Google Scholar
|
|
6
|
Bussolino F, Di Renzo MF, Ziche M, et al:
Hepatocyte growth factor is a potent angiogenic factor which
stimulates endothelial cell motility and growth. J Cell Biol.
119:629–641. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang YW, Su Y, Volpert OV and Vande Woude
GF: Hepatocyte growth factor/scatter factor mediates angiogenesis
through positive VEGF and negative thrombospondin 1 regulation.
Proc Natl Acad Sci USA. 100:12718–12723. 2003. View Article : Google Scholar
|
|
8
|
Jeffers M, Fiscella M, Webb CP, Anver M,
Koochekpour S and Vande Woude GF: The mutationally activated Met
receptor mediates motility and metastasis. Proc Natl Acad Sci USA.
95:14417–14422. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Webb CP, Taylor GA, Jeffers M, et al:
Evidence for a role of Met-HGF/SF during Ras-mediated
tumorigenesis/metastasis. Oncogene. 17:2019–2025. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakajima M, Sawada H, Yamada Y, et al: The
prognostic significance of amplification and overexpression of cMET
and c-erb B-2 in human gastric carcinomas. Cancer. 85:1894–1902.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee J, Seo JW, Jun HJ, et al: Impact of
MET amplification on gastric cancer: Possible roles as a novel
prognostic marker and a potential therapeutic target. Oncol Rep.
25:1517–1524. 2011.PubMed/NCBI
|
|
13
|
Tang Z, Zhao M, Ji J, et al:
Overexpression of gastrin and cMET protein involved in human
gastric carcinomas and intestinal metaplasia. Oncol Rep.
11:333–339. 2004.PubMed/NCBI
|
|
14
|
Chen CT, Kim H, Liska D, Gao S,
Christensen JG and Weiser MR: MET activation mediates resistance to
lapatinib inhibition of HER2-amplified gastric cancer cells. Mol
Cancer Ther. 11:660–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kneissl J, Keller S, Lorber T, et al:
Association of amphiregulin with the cetuximab sensitivity of
gastric cancer cell lines. Int J Oncol. 41:733–744. 2012.PubMed/NCBI
|
|
16
|
Oliner KD, Tang R, Anderson A, et al:
Evaluation of MET pathway biomarkers in a phase II study of
rilotumumab (R, AMG 102) or placebo (P) in combination with
epirubicin, cisplatin, and capecitabine (ECX) in patients (pts)
with locally advanced or metastatic gastric (G) or esophagogastric
junction (EGJ) cancer. Proc ASCO abs. 4005. 2012.
|
|
17
|
Catenacci DV, Henderson L, Xiao SY, et al:
Durable complete response of metastatic gastric cancer with
anti-Met therapy followed by resistance at recurrence. Cancer
Discov. 1:573–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cooper CS, Park M, Blair DG, et al:
Molecular cloning of a new transforming gene from a chemically
transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park M, Dean M, Cooper CS, et al:
Mechanism of met oncogene activation. Cell. 45:895–904. 1986.
View Article : Google Scholar
|
|
20
|
Park M, Dean M, Kaul K, Braun MJ, Gonda MA
and Vande Woude G: Sequence of MET protooncogene cDNA has features
characteristic of the tyrosine kinase family of growth-factor
receptors. Proc Natl Acad Sci USA. 84:6379–6383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bottaro DP, Rubin JS, Faletto DL, et al:
Identification of the hepatocyte growth factor receptor as the cMET
proto-oncogene product. Science. 251:802–804. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakamura T, Nishizawa T, Hagiya M, et al:
Molecular cloning and expression of human hepatocyte growth factor.
Nature. 342:440–443. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stoker M, Gherardi E, Perryman M and Gray
J: Scatter factor is a fibroblast-derived modulator of epithelial
cell mobility. Nature. 327:239–242. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peschard P and Park M: From Tpr-Met to
Met, tumorigenesis and tubes. Oncogene. 26:1276–1285. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ponzetto C, Bardelli A, Zhen Z, et al: A
multifunctional docking site mediates signaling and transformation
by the hepatocyte growth factor/scatter factor receptor family.
Cell. 77:261–271. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen L, Holgado-Madruga M, Maroun C, et
al: Association of the multisubstrate docking protein Gab1 with the
hepatocyte growth factor receptor requires a functional Grb2
binding site involving tyrosine 1356. J Biol Chem. 272:20811–20819.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mughal A, Aslam HM, Khan AM, Saleem S,
Umah R and Saleem M: Bcr-Abl tyrosine kinase inhibitors-current
status. Infect Agent Cancer. 8:232013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peters S and Adjei AA: MET: a promising
anticancer therapeutic target. Nat Rev Clin Oncol. 9:314–326. 2012.
View Article : Google Scholar
|
|
29
|
Yamamoto N, Mammadova G, Song RX, Fukami Y
and Sato K: Tyrosine phosphorylation of p145met mediated by EGFR
and Src is required for serum-independent survival of human bladder
carcinoma cells. J Cell Sci. 119:4623–4633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khoury H, Naujokas MA, Zuo D, et al: HGF
converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol
Biol Cell. 16:550–561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bauer TW, Somcio RJ, Fan F, et al:
Regulatory role of cMET in insulin-like growth factor-I
receptor-mediated migration and invasion of human pancreatic
carcinoma cells. Mol Cancer Ther. 5:1676–1682. 2006. View Article : Google Scholar
|
|
32
|
Uehara Y, Minowa O, Mori C, et al:
Placental defect and embryonic lethality in mice lacking hepatocyte
growth factor/scatter factor. Nature. 373:702–705. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Woolf AS, Kolatsi-Joannou M, Hardman P, et
al: Roles of hepatocyte growth factor/scatter factor and the met
receptor in the early development of the metanephros. J Cell Biol.
128:171–184. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bladt F, Riethmacher D, Isenmann S, Aguzzi
A and Birchmeier C: Essential role for the cMET receptor in the
migration of myogenic precursor cells into the limb bud. Nature.
376:768–771. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang YW and Vande Woude GF: HGF/SF-met
signaling in the control of branching morphogenesis and invasion. J
Cell Biochem. 88:408–417. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chmielowiec J, Borowiak M, Morkel M, et
al: cMET is essential for wound healing in the skin. J Cell Biol.
177:151–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Giordano S, Ponzetto C, Di Renzo MF,
Cooper CS and Comoglio PM: Tyrosine kinase receptor
indistinguishable from the cMET protein. Nature. 339:155–156. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Soman NR, Correa P, Ruiz BA and Wogan GN:
The TPR-MET oncogenic rearrangement is present and expressed in
human gastric carcinoma and precursor lesions. Proc Natl Acad Sci
USA. 88:4892–4896. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu J, Miehlke S, Ebert MP, et al:
Frequency of TPR-MET rearrangement in patients with gastric
carcinoma and in first-degree relatives. Cancer. 88:1801–1806.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee HE, Kim MA, Lee HS, et al: MET in
gastric carcinomas: comparison between protein expression and gene
copy number and impact on clinical outcome. Br J Cancer.
107:325–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Janjigian YY, Tang LH, Coit DG, et al: MET
expression and amplification in patients with localized gastric
cancer. Cancer Epidemiol Biomarkers Prev. 20:1021–1027. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Retterspitz MF, Monig SP, Schreckenberg S,
et al: Expression of {beta}-catenin, MUC1 and cMET in diffuse-type
gastric carcinomas: correlations with tumour progression and
prognosis. Anticancer Res. 30:4635–4641. 2010.
|
|
43
|
Park WS, Oh RR, Kim YS, et al: Absence of
mutations in the kinase domain of the Met gene and frequent
expression of Met and HGF/SF protein in primary gastric carcinomas.
APMIS. 108:195–200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsugawa K, Yonemura Y, Hirono Y, et al:
Amplification of the cMET, c-erbB-2 and epidermal growth factor
receptor gene in human gastric cancers: correlation to clinical
features. Oncology. 55:475–481. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Graziano F, Galluccio N, Lorenzini P, et
al: Genetic activation of the MET pathway and prognosis of patients
with high-risk, radically resected gastric cancer. J Clin Oncol.
29:4789–4795. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi J, Yao D, Liu W, et al: Frequent gene
amplification predicts poor prognosis in gastric cancer. Int J Mol
Sci. 13:4714–4726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schmidt L, Duh FM, Chen F, et al: Germline
and somatic mutations in the tyrosine kinase domain of the MET
proto-oncogene in papillary renal carcinomas. Nat Genet. 16:68–73.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Olivero M, Valente G, Bardelli A, et al:
Novel mutation in the ATP-binding site of the MET oncogene tyrosine
kinase in a HPRCC family. Int J Cancer. 82:640–643. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee JH, Han SU, Cho H, et al: A novel germ
line juxtamembrane Met mutation in human gastric cancer. Oncogene.
19:4947–4953. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Asaoka Y, Tada M, Ikenoue T, et al:
Gastric cancer cell line Hs746T harbors a splice site mutation of
cMET causing juxtamembrane domain deletion. Biochem Biophys Res
Commun. 394:1042–1046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Burgess T, Coxon A, Meyer S, et al: Fully
human monoclonal antibodies to hepatocyte growth factor with
therapeutic potential against hepatocyte growth
factor/cMET-dependent human tumors. Cancer Res. 66:1721–1729. 2006.
View Article : Google Scholar
|
|
52
|
Jun HT, Sun J, Rex K, et al: AMG 102, a
fully human anti-hepatocyte growth factor/scatter factor
neutralizing antibody, enhances the efficacy of temozolomide or
docetaxel in U-87 MG cells and xenografts. Clin Cancer Res.
13:6735–6742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gordon MS, Sweeney CS, Mendelson DS, et
al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a
fully human hepatocyte growth factor-neutralizing monoclonal
antibody, in a first-in-human study of patients with advanced solid
tumors. Clin Cancer Res. 16:699–710. 2010. View Article : Google Scholar
|
|
54
|
Iveson T, Donehower RC, Davidenko I, et
al: 6504 ORAL safety and efficacy of epirubicin, cisplatin, and
capecitabine (ECX) plus rilotumumab (R) as first-line treatment for
unresectable locally advanced (LA) or metastatic (M) gastric or
esophagogastric junction (EGJ) adenocarcinoma. Eur J Cancer.
47:S4432011. View Article : Google Scholar
|
|
55
|
First-line treatment for locally advanced
or metastatic mesenchymal epithelial transition factor
(MET)-positive gastric, lower esophageal, or gastroesophageal
junction (GEJ) adenocarcinoma (RILOMET-1). http://www.clinicaltrials.gov/ct2/show/NCT01697072.
Accessed May 17, 2013
|
|
56
|
MEGA (Met or EGFR inhibition in
gastroesophageal adenocarcinoma). FOLFOX alone or in combination
with AMG 102 or Panitumumab as first-line treatment in patients
with advanced gastroesophageal adenocarcinoma. http://www.clinicaltrials.gov/ct2/show/NCT01443065.
Accessed May 17, 2013
|
|
57
|
Martens T, Schmidt NO, Eckerich C, et al:
A novel one-armed anti-cMET antibody inhibits glioblastoma growth
in vivo. Clin Cancer Res. 12:6144–6152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Penuel E, Li C, Parab V, et al: HGF as a
Circulating biomarker of onartuzumab treatment in patients with
advanced solid tumors. Mol Cancer Ther. 12:1122–1130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jagoda EM, Lang L, Bhadrasetty V, et al:
Immuno-PET of the hepatocyte growth factor receptor Met using the
1-armed antibody onartuzumab. J Nucl Med. 53:1592–1600. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
A study of Onartuzumab (MetMAb) in
combination with mFOLFOX6 in patients with metastatic HER2-negative
gastroesophageal cancer. http://clinicaltrials.gov/ct2/show/NCT01590719.
Accessed May 15, 2013
|
|
61
|
A study of Onartuzumab (MetMAb) in
combination with mFOLFOX6 in patients with metastatic HER2-negative
and Met-positive gastroesophageal cancer (MetGastric). http://www.clinicaltrials.gov/ct2/show/NCT01662869.
Accessed May 15, 2013
|
|
62
|
Munshi N, Jeay S, Li Y, et al: ARQ 197, a
novel and selective inhibitor of the human cMET receptor tyrosine
kinase with antitumor activity. Mol Cancer Ther. 9:1544–1553. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Katayama R, Aoyama A, Yamori T, et al:
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to
cMET inhibition. Cancer Res. 73:3087–3096. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Muro K, Ryu M-H, Yasui H, et al: A phase
II study of tivantinib monotherapy in patients with previously
treated advanced or recurrent gastric cancer. Proc ASCO abs.x 4082.
2012.
|
|
65
|
Phase I/II trial of Tivantinib with FOLFOX
for the treatment of advanced solid tumors and previously untreated
metastatic adenocarcinoma of the distal esophagus, gastroesophageal
junction or stomach. http://www.clinicaltrials.gov/ct2/show/NCT01611857.
Accessed May 15, 2013
|
|
66
|
Okamoto W, Okamoto I, Arao T, et al:
Antitumor action of the MET tyrosine kinase inhibitor crizotinib
(PF-02341066) in gastric cancer positive for MET amplification. Mol
Cancer Ther. 11:1557–1564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lennerz JK, Kwak EL, Ackerman A, et al:
MET amplification identifies a small and aggressive subgroup of
esophagogastric adenocarcinoma with evidence of responsiveness to
crizotinib. J Clin Oncol. 29:4803–4810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Qian F, Engst S, Yamaguchi K, et al:
Inhibition of tumor cell growth, invasion, and metastasis by
EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF
receptor tyrosine kinases. Cancer Res. 69:8009–8016. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kataoka Y, Mukohara T, Tomioka H, et al:
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs,
inhibits growth of gastric cancer cell lines by blocking
inter-receptor tyrosine kinase networks. Invest New Drugs.
30:1352–1360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shah MA, Wainberg ZA, Catenacci DV, et al:
Phase II study evaluating 2 dosing schedules of oral foretinib
(GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic
gastric cancer. PLoS One. 8:e540142013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Freidlin B, McShane LM, Polley MY and Korn
EL: Randomized phase II trial designs with biomarkers. J Clin
Oncol. 30:3304–3309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yakes FM, Chen J, Tan J, et al:
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor,
simultaneously suppresses metastasis, angiogenesis, and tumor
growth. Mol Cancer Ther. 10:2298–2308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Schoffski P, Sgroi M, Burris HA, Lutzky J,
Rearden T, Sikic B, et al: Phase 2 randomized discontinuation trial
(RDT) of XL184 in patients (pts) with advanced solid tumors.
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics EJC Supplements. 8:1172010.
|
|
74
|
Kim MJ, Nam HJ, Kim HP, et al: OPB-31121,
a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway
and exhibits an antitumor activity in gastric cancer cells. Cancer
Lett. 335:145–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Oh D, Han S, Kim TM, et al: A phase I,
open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in
patients with advanced solid tumors. J Clin Oncol.
28:e130562010.
|
|
76
|
Camacho LH, Moulder SL, LoRusso PM, et al:
First in human phase I study of MK-2461, a small molecule inhibitor
of cMET, for patients with advanced solid tumors. J Clin Oncol.
26(Suppl 15): abs. 14657. 2008.
|
|
77
|
Falchook GS, Fu S, Amin HM, Piha-Paul SA,
Hong DS, Naing A, et al: 1245 Poster Phase I dose-escalation study
of the oral selective C-Met inhibitor EMD 1204831 in patients with
advanced solid tumours. Eur J Cancer. 47:S1582011.
|
|
78
|
Buchanan SG, Hendle J, Lee PS, et al:
SGX523 is an exquisitely selective, ATP-competitive inhibitor of
the MET receptor tyrosine kinase with antitumor activity in vivo.
Mol Cancer Ther. 8:3181–3190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Awazu Y, Nakamura K, Mizutani A, et al: A
Novel Inhibitor of cMET and VEGF Receptor Tyrosine Kinases with a
Broad Spectrum of In Vivo Antitumor Activities. Mol Cancer Ther.
12:913–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Oh YM, Song YJ, Lee SB, et al: A new
anti-cMET antibody selected by a mechanism-based dual-screening
method: therapeutic potential in cancer. Mol Cells. 34:523–529.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nakagawa T, Tohyama O, Yamaguchi A, et al:
E7050: a dual cMET and VEGFR-2 tyrosine kinase inhibitor promotes
tumor regression and prolongs survival in mouse xenograft models.
Cancer Sci. 101:210–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Goetsch L, Gonzalez A, Geronimi F,
Fabre-Lafay S, et al: Single or combined in vivo therapies of
cancer with h224G11, a humanized antibody targeting the cMET
receptor. Mol Cancer Ther. 8:B1272009. View Article : Google Scholar
|
|
83
|
Corso S, Ghiso E, Cepero V, et al:
Activation of HER family members in gastric carcinoma cells
mediates resistance to MET inhibition. Mol Cancer. 9:1212010.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Qi J, McTigue MA, Rogers A, et al:
Multiple mutations and bypass mechanisms can contribute to
development of acquired resistance to MET inhibitors. Cancer Res.
71:1081–1091. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lee NV, Lira ME, Pavlicek A, et al: A
novel SND1-BRAF fusion confers resistance to cMET inhibitor
PF-04217903 in GTL16 cells through [corrected] MAPK activation.
PLoS One. 7:e396532012.PubMed/NCBI
|
|
86
|
Cepero V, Sierra JR, Corso S, et al: MET
and KRAS gene amplification mediates acquired resistance to MET
tyrosine kinase inhibitors. Cancer Res. 70:7580–7590. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Marangoni E, Vincent-Salomon A, Auger N,
et al: A new model of patient tumor-derived breast cancer
xenografts for preclinical assays. Clin Cancer Res. 13:3989–3998.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Amemiya H, Kono K, Mori Y, et al: High
frequency of cMET expression in gastric cancers producing
alpha-fetoprotein. Oncology. 59:145–151. 2000. View Article : Google Scholar : PubMed/NCBI
|
